Modified SAMe-TT2R2 score for predicting the therapeutic range of digoxin.

Mehmet Baran KarataşYiğit ÇangaNizamettin Selçuk YelgeçAhmet ZenginÖzge GüzelburçSemih ErenAyşe Emre

Published in: Herz (2020)

Digoxin is still widely used in the treatment of heart failure and AF despite concerns about the increased risk of mortality when levels are oTR. In the present study, the modified SAMe-TT2R2 score was found to be an independent predictor of oTR. This score may aid clinicians in identifying patients who are more likely to benefit from digoxin therapy.

Keyphrases

heart failure
end stage renal disease
newly diagnosed
chronic kidney disease
atrial fibrillation
palliative care
cardiovascular events
risk factors
stem cells
type diabetes
cardiovascular disease
coronary artery disease
patient reported outcomes
bone marrow
mesenchymal stem cells